Lookup NU author(s): Dr Richard Scott,
Dr Keith Healy,
Dr Alistair Henderson,
Emeritus Professor Bill Clegg,
Dr Ross Harrington,
Professor Bernard Golding
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Metabolism of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (anagrelide), a drug for treating essential thrombocythemia, gives 6,7-dichloro-3-hydroxy-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (3-hydroxyanagrelide) and 2-amino-5,6-dichloro-3,4-dihydroquinazoline. To enable the properties of 3-hydroxyanagrelide to be fully evaluated, the racemic compound has been synthesized. In pH 7.4 aqueous buffer 3-hydroxyanagrelide readily equilibrates with an isomer, 6,7-dichloro-1-hydroxy-3,5-dihydroimidazo[1,2-alpha]-quinazolin-2-one,and is also hydrolyzed to 2-amino-5,6-dichloro-3,4-dihydroquinazoline. 3-Hydroxyanagrelide (half-life 40 hours) was the dominant species at equilibrium and it was concluded that the equilibration and decomposition are sufficiently slow that published assays of 3-hydroxyanagrelide are reliable.
Author(s): Scott RB, Downey KM, Healy KP, Henderson AP, Robinson CL, Clegg W, Harrington RW, Franklin R, Golding BT
Publication type: Article
Publication status: Published
Print publication date: 30/10/2012
ISSN (print): 0385-5414
ISSN (electronic): 1881-0942
Publisher: Japan Institute of Heterocyclic Chemistry
Altmetrics provided by Altmetric